ISCT Asia 2026 Singapore

The global cell and gene therapy community is heading to Singapore ISCT Asia 2026 Regional Meeting brings together regional leaders to address the science, policy regulatory framework, and market realities driving the sector forward.

- Explore the full clinical translation pipeline, from early discovery to patient impact.
- Gain insights from key opinion leaders presenting breakthrough research and forward-looking ideas in cell and gene therapy.
- Participate in interactive discussions that confront the practical challenges of translating scientific advances into real-world treatments.

Come and find the ACRO Llama at our booth #17!

We are excited to announce that we will be presenting at ISCT Asia 2026 in Singapore!

Description: Cell and gene therapies leave no room for error. Unlike traditional biologics, every reagent decision in manufacturing directly impacts patient outcomes — yet CGT workflows bring unique complexity: variable matrices, tight IND timelines, and evolving regulatory expectations that traditional reagent portfolios weren't built to meet.

Our solution: a comprehensive portfolio spanning the full CGT continuum — GMP-grade cytokines and CAR target proteins, validated cell line models, and recombinant factor C endotoxin detection. Purpose-built for CGT's demands, this end-to-end offering gives researchers and manufacturers the precision and reliability to strengthen lot release decisions, accelerate IND timelines, and confidently bridge the gap between cutting-edge research and safe, scalable delivery of life-changing therapies.

Objectives:

1. Recap of CGT challenges
2. Fit for purpose tool at every stage of CGT
3. Choosing the right QC solutions